Deletion of angiotensin-converti enzyme 2 promotes the development of atherosclerosis and arterial neointima formation

Cardiovascular Research

Volumn 101, Issue 2, 2014, Pages 236-246

  Sahara, Makoto ^a,b   Ikutomi, Masayasu ^a   Morita, Toshihiro ^a   Minami, Yoshiyasu ^a   Nakajima, Toshiaki ^a   Hirata, Yasunobu ^a   Nagai, Ryozo ^a,c   Sata, Masataka ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b KAROLINSKA INSTITUTE   (Sweden)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Angiotensin II; Angiotensin converting enzyme 2 remodelling; Atherosclerosis; C Jun N terminal kinase; Vascular disease

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APOLIPOPROTEIN E; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; DIPEPTIDYL CARBOXYPEPTIDASE; PROTEIN KINASE INHIBITOR; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTERIAL NEOINTIMA FORMATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; GENE DELETION; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; MACROPHAGE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR DISEASE; VASCULAR LESION; VASCULITIS; ANGIOTENSIN-CONVERTING ENZYME 2 REMODELLING; ANIMAL; AORTA; AORTA DISEASE; BLOOD VESSEL INJURY; C-JUN N-TERMINAL KINASE; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; FEMORAL ARTERY; GENETIC PREDISPOSITION; GENETICS; INJURY; KNOCKOUT MOUSE; METABOLISM; NEOINTIMA; PATHOLOGY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME 2 REMODELLING; ATHEROSCLEROSIS; C-JUN N-TERMINAL KINASE; VASCULAR DISEASE;

ANGIOTENSIN II; ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMORAL ARTERY; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; INFLAMMATION MEDIATORS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; PEPTIDYL-DIPEPTIDASE A; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSFECTION; VASCULAR SYSTEM INJURIES;

EID: 84893040529     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt245     Document Type: Article

References (20)

1. Cooper LT Jr. Myocarditis. N Engl J Med 2009;360:1526-1538
2. Caforio AL, Tona F, Bottaro S, Vinci A, Dequal G, Daliento L et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity 2008;41:35-45
3. Watanabe K, SukumaranV, Veeraveedu PT, Thandavarayan RA, Gurusamy N,MaMet al. Regulation of inflammation and myocardial fibrosis in experimental autoimmune myocarditis. Inflamm Allergy Drug Targets 2011;10:218-225
4. Yamashita T, IwakuraT, Matsui K, Kawaguchi H, Obana M, HayamaAet al. IL-6-mediated Th17 differentiation through RORgammat is essential for the initiation of experimental autoimmune myocarditis. Cardiovasc Res 2011;91:640-648
5. Mahrholdt H,Wagner A, Deluigi CC, Kispert E, Hager S, MeinhardtGet al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 2006; 114:1581-1590
6. Papageorgiou AP, Swinnen M, Vanhoutte D, VandenDriessche T, Chuah M, Lindner D et al. Thrombospondin-2 prevents cardiac injury and dysfunction in viral myocarditis through the activation of regulatory T-cells. Cardiovasc Res 2012;94:115-124
7. Merad M, Manz MG. Dendritic cell homeostasis. Blood 2009;113:3418-3427
8. Leuschner F, Katus HA, Kaya Z. Autoimmune myocarditis: Past, present and future. J Autoimmun 2009;33:282-289
9. Baughman KL. Diagnosis of myocarditis: Death of Dallas criteria. Circulation 2006;113: 593-595
10. Blyszczuk P, Valaperti A, Eriksson U. Future therapeutic strategies in inflammatory cardiomyopathy: Insights from the experimental autoimmune myocarditis model. Cardiovasc Hematol Disord Drug Targets 2008;8:313-321
11. Liu K, Victora GD, Schwickert TA, Guermonprez P, Meredith MM, YaoK et al. In vivo analysis of dendritic cell development and homeostasis. Science 2009;324:392-397
12. Mahnke K, Johnson TS, Ring S, Enk AH. Tolerogenic dendritic cells and regulatory T cells: A two-way relationship. J Dermatol Sci 2007;46:159-167
13. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 2010;108:111-165
14. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: Cytokine modulation comes of age. Blood 2006;108:1435-1440
15. Tisch R. Immunogenic versus tolerogenic dendritic cells: A matter of maturation. Int Rev Immunol 2010;29:111-118
16. Liu W, Li WM, Gao C, Sun NL. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats. J Autoimmun 2005;25: 258-263
17. Torres-Aguilar H, Blank M, Jara LJ, Shoenfeld Y. Tolerogenic dendritic cells in autoimmune diseases: Crucial players in induction and prevention of autoimmunity. Autoimmun Rev 2010;10:8-17
18. Thakker P, LeachMW, KuangW, Benoit SE, Leonard JP, Marusic S. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol 2007;178:2589-2598
19. Tang J, ZhuW, Silver PB, Su SB, Chan CC, Caspi RR. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: Initial encounter with autoantigen defines disease phenotype. J Immunol 2007;178:5578-5587
20. Ke Y, Liu K, Huang GQ, Cui Y, Kaplan HJ, Shao Het al. Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol 2009;182:3183-3190